Selecta Biosciences, Inc. (NASDAQ:SELB) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET
Company Participants
Blaine Davis - CFO
Carsten Brunn - CEO, President & Director
Peter Traber - Chief Medical Officer
Conference Call Participants
Joseph Schwartz - SVB Securities
Kristen Kluska - Cantor Fitzgerald
John Newman - Canaccord Genuity
Dipesh Patel - H.C. Wainwright & Co.
Uy Ear - Mizuho Securities
Gil Blum - Needham & Company
Operator
Good morning, and thank you for joining the Selecta Biosciences First Quarter 2023 Earnings Call. [Operator Instructions]. I would now like to turn the call over to Blaine Davis, Chief Financial Officer at Selecta. Please go ahead.
Blaine Davis
Thank you, and good morning, everyone. Welcome to our first quarter 2023 financial results and business update conference call. The press release reporting our financial results is available in the Investor and Media section of Selecta's website at www.selectabio.com, and in our quarterly report on Form 10-Q for the quarter ended March 31, 2023, which was filed earlier this morning with the Securities and Exchange Commission of the SEC.
Joining me on today's call are Carsten Brunn, President and Chief Executive Officer; Kate Kishimoto, Chief Scientific Officer; and Peter Traber, our Chief Medical Officer.
During today's call, we will be making certain forward-looking statements, including, without limitation, statements about the potential safety, efficacy and regulatory and clinical progress of our product candidates, our financial projections and our future expectations, plans, partnerships and prospects. These statements are subject to various risks that are described in the filings made with the SEC, including our most recent annual report on Form 10-K and quarterly report on Form 10-Q.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today, May 4, 2023, and Selecta disclaims any obligation to update such statements, except as required by law, even if management's views change.
With that, let me turn it over to Carsten.
Carsten Brunn
Good morning. I appreciate everyone taking the time joining us today. The first quarter of 2023 was marked by a significant milestone with the announcement of positive results from 2 Phase III studies of SEL-212 in chronic refractory gout, DISSOLVE I and II, both of which met their primary endpoints. As a reminder, SEL-212 is a combination drug product candidates consisting of 2 components. The first component is pegadricase, a potent enzyme that has been observed to reduce serum uric in refractory gout patients who continue to have serious disease symptoms such as debilitating joint pain and disfiguring tissue deposits of urate called tophi.